de Boysson H, Barakat C, Dumont A, et al. - According to pragmatic and updated data generated in this real-life study, glucocorticoid (GC) tolerance remains more noteworthy than ever. Based on findings, carefully monitoring GC-associated adverse events (AEs) during follow-up is recommended. Results encourage GC-sparing strategies in some cases.

• In this study of 100 patients with giant cell arteritis, patients’ self-reported GC-related AEs were evaluated.

• Of 90 patients included, 99% (n=89) experienced at least one GC-related AE (median 6 [1—11]).

• Of patients, 90% encountered cognitive and psychological changes, primarily insomnia (72%), and 70% developed cutaneous changes and muscle loss, with frequent impairment of physical autonomy linked with this event.

• In 49% of patients, metabolic issues, especially weight gain (40%) and diabetes mellitus (20%), occurred.

• Vision troubles and bone fractures occurred in 42% and 9% of patients, respectively, and more often in those treated with GCs for >18 months.

• Cardiovascular changes and infections were reported by 30% and 26% of patients, respectively.